EXS21546
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 14/100
14
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumours
Conditions
Advanced Solid Tumours
Trial Timeline
Apr 11, 2023 → Oct 23, 2023
NCT ID
NCT05920408About EXS21546
EXS21546 is a phase 1/2 stage product being developed by Biotrial for Advanced Solid Tumours. The current trial status is terminated. This product is registered under clinical trial identifier NCT05920408. Target conditions include Advanced Solid Tumours.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumours were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05920408 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Advanced Solid Tumours